Ad
related to: fgfr inhibitor
Search results
J&J (JNJ) Seeks Approval for Bladder Cancer Drug in Europe
Zacks via Yahoo Finance· 8 months agoJ&J's (JNJ) erdafitinib is already marketed as Balversa in the United States for FGFR-altered...
Oppenheimer Says These 2 Stocks Have Double-Digit Gains in Sight
TipRanks via Yahoo Finance· 1 year ago2023 is well underway now, and the key story is the sudden change in sentiment on the financial...
Incyte (INCY) Gets FDA Nod for Label Expansion of Pemazyre
Zacks via Yahoo Finance· 2 years agoIncyte (INCY) obtains FDA approval for Pemazyre for a second indication - the treatment of adults...
Personalised drug therapy hope for bile duct cancer patients
Press Association News via AOL· 1 year agoA drug treatment for bile duct cancer patients with a rare mutation has been shown to improve...
Incyte's (INCY) Pemazyre Gets Approval to Treat MLNs in Japan
Zacks via Yahoo Finance· 1 year agoIncyte INCY announced that it has received approval for treating patients with myeloid or lymphoid...
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 1 year agoIncyte Corporation INCY is scheduled to release its fourth-quarter and full-year 2022 results on Feb...
These 2 “Strong Buy” Penny Stocks Could Surge 200% (or More), Says Wedbush
TipRanks via Yahoo Finance· 12 months agoInvestors are constantly looking for stocks that will yield massive returns. That being said,...
Incyte's (INCY) Q3 Earnings and Revenues Miss Estimates
Zacks via Yahoo Finance· 2 years agoIncyte's (INCY) earnings and revenues fall shy of estimates in the third quarter of 2022. The...
Over 100% Upside: Analysts See an Appealing Entry Point in These 3 ‘Strong Buy’ Stocks
TipRanks via Yahoo Finance· 2 years agoAfter July’s exceptional surge, the markets steadied during early August with the S&P 500 up by a...
Tyra Biosciences Inc (TYRA) Reports Increased R&D Investments Amid Pipeline Progress
GuruFocus.com via Yahoo Finance· 2 months agoNet Loss: Q4 net loss widened to $22.8 million from $12.9 million in the same period last year. Research and Development Expenses: R&D expenses increased to $20.7 million in Q4, up from $10.4 ...